Cagrilintide Dose and Frequency: A Trial-Based Overview

Trust signals

> Reviewed by FormBlends Medical Team · Last updated May 2026 · 9 sources cited

Key Takeaways

• Cagrilintide is investigational and not FDA-approved; there is no approved patient dose
• Phase 2 trials tested 0.3, 0.6, 1.2, 2.4, and 4.5 mg weekly; the 2.4 mg dose is the most-studied and most-commercially-likely
• The drug is injected subcutaneously once weekly, similar to semaglutide and tirzepatide schedules
• Titration starts low (typically 0.3 mg) and increases over weeks to target dose
• FormBlends does not prescribe or supply cagrilintide; trial dosing is research protocol, not patient guidance

Direct answer

Cagrilintide has been tested in clinical trials at doses of 0.3 to 4.5 mg administered subcutaneously once weekly. The most-studied dose is 2.4 mg weekly, which produced approximately 10% weight loss at 26 weeks in the Lau et al. 2021 phase 2 trial. Trials start at a low dose (typically 0.3 mg) and titrate up every 2-4 weeks to manage GI side effects. Cagrilintide is investigational and not FDA-approved. There is no patient-approved dose; trial dosing should not be interpreted as a self-administration protocol.

Table of contents

1. Important framing: what "dose" means for an investigational drug
2. Dose ranges tested in published trials
3. Why 2.4 mg became the focus dose
4. The titration schedule used in trials
5. Injection technique and frequency
6. Why dose-response flattens at higher doses
7. How CagriSema combines cagrilintide and semaglutide dosing
8. The gray-market dosing problem
9. The contrary view: dose may differ in commercial labeling
10. Decision framework for patients considering trials
11. FAQ
12. Sources

Important framing: what "dose" means for an investigational drug

This article describes doses studied in clinical trials. None of these doses constitute medical guidance or a self-administration protocol. Several reasons matter:

First, cagrilintide is investigational. It is not FDA-approved. There is no labeling, no patient information leaflet, and no prescriber guidance. Any use outside an authorized clinical trial is unauthorized.

Second, trial doses are administered under medical supervision. Patients in trials are monitored for tolerability, blood pressure, vital signs, lab abnormalities, and adverse events. Self-administration outside of supervision lacks all of these safety nets.

Third, trial products are quality-tested. The cagrilintide used in clinical trials is manufactured under FDA-recognized standards. Products labeled as cagrilintide from gray-market sources do not have verified identity, purity, or sterility.

Fourth, trial dosing protocols include titration steps that minimize side effects. Skipping titration produces nausea and vomiting at rates that lead many patients to discontinue or to develop dehydration and electrolyte complications.

If you are interested in cagrilintide for weight management, the appropriate path is to discuss with your clinician and, if relevant, to ask about enrollment in active clinical trials (clinicaltrials.gov has the most current listing).

Dose ranges tested in published trials

The pivotal phase 2 monotherapy trial (Lau et al., The Lancet 2021) tested five active doses against placebo and a liraglutide comparator.

Dose	Weight loss at 26 weeks (mean)	Notable side effect rates
Placebo	~3%	Baseline rates
Cagrilintide 0.3 mg	~6%	Nausea low
Cagrilintide 0.6 mg	~6.8%	Nausea moderate
Cagrilintide 1.2 mg	~7.4%	Nausea moderate
Cagrilintide 2.4 mg	~10.1%	Nausea higher, manageable
Cagrilintide 4.5 mg	~10.8%	Nausea highest, more discontinuation
Liraglutide 3.0 mg (daily)	~9.0%	GLP-1 class side effects

The 2.4 mg dose produced clearly better weight loss than lower doses, with proportional tolerability. The 4.5 mg dose produced only marginally more weight loss with what appeared to be a worse side-effect tradeoff.

Subsequent CagriSema trials have used 2.4 mg of cagrilintide combined with 2.4 mg of semaglutide as the standard dose. This matches the semaglutide weight-management dose used in Wegovy (2.4 mg weekly).

Why 2.4 mg became the focus dose

Several reasons converged on 2.4 mg as the development priority.

The efficacy plateau. Beyond 2.4 mg, additional dose did not produce meaningfully more weight loss in the Lau et al. trial. The 0.7 percentage point difference between 2.4 mg and 4.5 mg is small relative to the variability across patients.

Tolerability. At higher doses, nausea and other GI symptoms became more prominent. The discontinuation rate for adverse events increased at 4.5 mg compared to 2.4 mg.

Symmetry with semaglutide. The Wegovy weight-management dose of semaglutide is 2.4 mg weekly. Designing CagriSema as a 2.4 mg + 2.4 mg fixed-dose combination simplifies manufacturing, dose escalation, and patient instructions.

Cost of goods. While not a primary clinical reason, lower-dose products are cheaper to manufacture and stockpile. Selecting the lowest dose with full efficacy is a practical choice.

Statistical efficiency in subsequent trials. With a focused target dose, phase 3 trials can enroll patients on a single primary dose rather than spreading across multiple. This produces tighter confidence intervals on efficacy and side effects.

For these reasons, 2.4 mg weekly is the dose patients most commonly encounter in CagriSema-related coverage and in subsequent published trial summaries.

The titration schedule used in trials

Cagrilintide is titrated gradually to manage GI side effects. The schedule used in Lau et al. and subsequent CagriSema trials:

Weeks	Dose	Purpose
1-2	0.3 mg weekly	Starting dose, allows initial tolerability
3-4	0.6 mg weekly	First titration step
5-6	1.2 mg weekly	Halfway point
7-8	1.7 mg weekly	Intermediate dose
9+	2.4 mg weekly	Target maintenance dose

This schedule reaches target dose at week 9, which is similar to the semaglutide titration schedule for Wegovy. Slower titration (longer at each step) produces fewer adverse events but delays reaching effective dose. Faster titration produces more side effects, higher discontinuation, and potentially better short-term weight loss.

Most clinical experience suggests the 9-week titration is a reasonable balance for patients with no specific tolerability concerns. Patients with a history of severe GI sensitivity to medications may need slower titration. Patients with established GLP-1 tolerance may tolerate faster titration in clinical practice, though this is not standardized.

Injection technique and frequency

Cagrilintide is administered by subcutaneous injection once weekly. Subcutaneous means in the fatty layer beneath the skin, not into a muscle or vein. Common injection sites:

• Abdomen (avoiding the area immediately around the navel)
• Front of thigh
• Back of upper arm

Patients in trials rotate sites to avoid lipohypertrophy (fatty tissue buildup at repeated injection sites). The needle is typically a short, fine gauge (similar to GLP-1 medication needles), and the injection itself is brief.

Pre-filled pens are the standard delivery format in development. In trials, patients learn injection technique from study staff and practice under supervision before self-administering at home. The technique is comparable to semaglutide or tirzepatide self-injection.

Weekly cadence is supported by cagrilintide's half-life of approximately 7 days. Plasma levels remain relatively stable between weekly doses. Missing a single dose typically does not produce a dramatic decline in clinical effect, though missed doses should be reported to the study team.

Why dose-response flattens at higher doses

The Lau et al. data shows clear efficacy gains from 0.3 to 2.4 mg, then a flattening between 2.4 and 4.5 mg. This pattern is common in receptor agonist drugs.

Mechanistically:

• At low doses, plasma levels are insufficient to occupy enough receptors for full clinical effect
• As dose increases, more receptors are occupied, and clinical effect grows proportionally
• At higher doses, receptor occupancy approaches saturation; additional drug produces diminishing additional effect
• Side effects, which may operate through different receptor pathways or off-target effects, can continue to scale with dose even after the primary effect saturates

For cagrilintide, the dose-response curve flattens around 2.4 mg, suggesting receptor occupancy is near maximal at that dose. Pushing to 4.5 mg adds little efficacy but increases side-effect exposure.

This is the basis for the development team's choice to focus on 2.4 mg. The drug is operating near its mechanistic ceiling at that dose; additional dosing offers little upside.

How CagriSema combines cagrilintide and semaglutide dosing

The CagriSema fixed-dose combination delivers 2.4 mg of cagrilintide plus 2.4 mg of semaglutide in a single weekly subcutaneous injection. The doses match the standard weight-management doses of each component.

Titration for CagriSema (in trials):

• Weeks 1-4: lower combined dose with both components below target
• Weeks 5-12: stepwise increase of both components
• Weeks 13+: full 2.4 mg + 2.4 mg target dose

The mechanism rationale: cagrilintide and semaglutide act through different receptors (amylin and GLP-1, respectively). Combining them activates complementary pathways, potentially producing greater appetite suppression and weight loss than either alone.

The REDEFINE-1 phase 3 readout supported this conceptually. CagriSema produced approximately 22.7% mean weight loss at 68 weeks, compared to approximately 14.9% for semaglutide alone in earlier STEP 1 data. The CagriSema number is comparable to tirzepatide's 22.5% in SURMOUNT-1 through a different mechanism.

Whether the incremental benefit of cagrilintide on top of semaglutide justifies the additional cost, complexity, and side-effect burden is a question commercial and regulatory analysis will address.

The gray-market dosing problem

Some online sellers offer products labeled as cagrilintide with dosing instructions written by unofficial sources. These instructions are unreliable for several reasons.

Identity verification. Gray-market sellers do not have to prove that what is in the vial matches the label. Independent testing of products labeled as semaglutide or tirzepatide from unauthorized suppliers has found substantial variation, including products containing no active ingredient or different drugs entirely. The same risk applies to products labeled as cagrilintide.

Concentration variability. Even if the product contains cagrilintide, the labeled concentration may not match actual concentration. A patient who carefully calculates a "2.4 mg" dose based on a labeled concentration may receive a substantially different actual dose.

Sterility. Injectable products require sterile manufacturing. Gray-market suppliers operate outside FDA quality oversight. Contamination with bacteria, endotoxins, or particulates is a real risk.

No medical supervision. Trial patients have access to study teams for managing side effects, lab monitoring, and dose adjustment. Self-injecting from a gray-market vial without supervision means GI side effects, blood pressure changes, or rare adverse events have no clinical safety net.

Patient communities sometimes share dose protocols developed for gray-market use. FormBlends does not endorse or facilitate these protocols. The medical and regulatory risk is significant.

The contrary view: dose may differ in commercial labeling

The 2.4 mg dose used in trials is the development priority, but commercial labeling could differ. Several scenarios:

FDA labeling might recommend a different dose range based on full phase 3 data. If a lower dose produces acceptable efficacy with better tolerability in a subgroup analysis, labeling might recommend 1.7 mg or 2.0 mg as the standard target with optional escalation to 2.4 mg.

Labeling might recommend slower titration than trials used. If real-world tolerability in less-supervised settings is worse than in trials, the FDA may require a more conservative titration schedule.

Labeling might recommend cap doses for specific patient populations. Patients with hepatic impairment, renal impairment, or specific drug interactions might be limited to lower doses.

CagriSema labeling (if approved) might differ from monotherapy cagrilintide labeling. The combination's dosing may be locked at 2.4 mg + 2.4 mg or might offer alternative ratios.

Patients should rely on FDA-approved labeling once available, not on trial-era dosing assumptions.

Decision framework for patients considering trials

If you are interested in accessing cagrilintide today, clinical trial participation is the only legitimate path.

To explore trial participation:

1. Search clinicaltrials.gov for "cagrilintide" or "CagriSema" to find currently enrolling trials
2. Verify enrollment criteria (BMI, comorbidities, prior weight loss attempts, contraindications)
3. Contact the trial site listed in the registry
4. Discuss with your current clinician whether trial participation makes sense given your health profile

If trial participation is not feasible or you do not match enrollment criteria, currently available alternatives include:

• FDA-approved semaglutide (Wegovy) for similar mechanism without the amylin component
• FDA-approved tirzepatide (Zepbound) for greater mean weight loss
• Older amylin pathway option: pramlintide (Symlin), FDA-approved for diabetes, used off-label rarely for weight loss

Do not source cagrilintide from unauthorized suppliers. The risk profile is not acceptable for the clinical benefit, especially when alternative approved therapies exist.

FAQ

How much cagrilintide can I take weekly?

Cagrilintide is investigational and not FDA-approved, so there is no approved patient dose. In phase 2 trials, cagrilintide was tested at 0.3, 0.6, 1.2, 2.4, and 4.5 mg weekly. The 2.4 mg dose became the focus for further development based on the efficacy-to-tolerability balance. Higher doses produced only marginally more weight loss with potentially more side effects. FormBlends does not prescribe or supply cagrilintide.

What is the starting dose of cagrilintide?

In clinical trials, cagrilintide was started at 0.3 mg weekly to allow GI tolerability to develop. The dose was increased every 2-4 weeks toward the target dose (typically 2.4 mg). Patients should not interpret trial dosing as a self-administration protocol; cagrilintide is investigational and any access outside a trial is unauthorized.

How much cagrilintide should I take?

There is no FDA-approved dose for cagrilintide because the drug is not approved. Patients should not be taking cagrilintide outside of an authorized clinical trial. Online dose recommendations from unofficial sources do not reflect medical guidance. The trials have used 2.4 mg weekly as the primary dose, but this is research dosing, not patient dosing.

How often is cagrilintide injected?

Once weekly, by subcutaneous injection. The drug has a half-life of approximately 7 days, supporting weekly dosing with stable plasma levels. This is similar to semaglutide and tirzepatide weekly injection schedules. The older amylin analog pramlintide (Symlin) requires three-times-daily dosing; cagrilintide's long-acting structure eliminates that frequency.

Why is 2.4 mg the most-studied dose?

The Lau et al. 2021 phase 2 trial found that 2.4 mg weekly produced approximately 10% weight loss with manageable side effects. The 4.5 mg dose produced only marginally more weight loss (~10.8%) with possibly more GI side effects, suggesting diminishing returns. 2.4 mg also matches the semaglutide weight-loss dose, simplifying the fixed-dose CagriSema combination.

Can cagrilintide be combined with other GLP-1 drugs?

In clinical trials, cagrilintide has been combined with semaglutide (the CagriSema combination). Combinations with tirzepatide, retatrutide, or other GLP-1 medications have not been formally tested in human trials. Patients should not combine cagrilintide with any other drug outside of physician supervision; the safety and efficacy of unstudied combinations are unknown.

How is cagrilintide injected?

In clinical trials, cagrilintide is administered as a subcutaneous injection in the abdomen, thigh, or upper arm. The technique is similar to other GLP-1 injectables. Injection site rotation is standard practice to prevent lipohypertrophy. Patients in trials receive specific instructions from study staff; outside of trials, cagrilintide is not legally available.

Related guides

• How to Reconstitute Cagrilintide: An Educational Overview
• TRIUMPH-4 Trial Results: Retatrutide for Knee Osteoarthritis (Overview)
• Retatrutide 1mg Dose Clinical Trial Data
• Tool: dosage calculator

Sources

1. Lau DCW, Erichsen L, Francisco AM, et al. Once-weekly cagrilintide for weight management in people with overweight and obesity. The Lancet. 2021;398:2160-2172.
2. Enebo LB, Berthelsen KK, Kankam M, et al. Concomitant administration of cagrilintide with semaglutide 2.4 mg. The Lancet. 2021;397:1736-1748.
3. Novo Nordisk. REDEFINE-1 Phase 3 results, press release. December 2024.
4. Hay DL, Chen S, Lutz TA, et al. Amylin: pharmacology, physiology, and clinical potential. Pharmacological Reviews. 2015;67(3):564-600.
5. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. NEJM. 2021;384:989-1002. (STEP 1)
6. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. NEJM. 2022;387:205-216. (SURMOUNT-1)
7. ClinicalTrials.gov. Registry of active cagrilintide and CagriSema trials. Accessed May 2026.
8. U.S. Food and Drug Administration. Symlin (pramlintide acetate) Prescribing Information. 2005, revised.
9. Novo Nordisk. Pipeline development updates for cagrilintide and CagriSema. novonordisk.com.

Footer disclaimers

Platform Disclaimer. FormBlends provides clinician-supervised weight management with FDA-approved and 503A-compounded GLP-1 medications. Cagrilintide is investigational, not on our formulary, and not available through FormBlends. We do not have a commercial relationship with Novo Nordisk. Trial dosing information in this article is descriptive, not prescriptive.

Compounded Medication Notice. 503A compounding of cagrilintide is not authorized through standard FDA shortage pathways. Some compounding pharmacies have offered "research peptides" labeled as cagrilintide; these are not equivalent to FDA-recognized clinical trial materials and are not FDA-approved. Patients should not pursue access through these channels.

Results Disclaimer. Trial dose-response data cited in this article reflect averages from published clinical studies. Individual response varies. Trial protocols include monitoring and safety nets that self-administration outside of trials lacks.

Trademark Notice. Cagrilintide and CagriSema are development names for investigational compounds owned by Novo Nordisk A/S. Wegovy, Ozempic, Saxenda, and Symlin are registered trademarks of Novo Nordisk. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends has no affiliation with Novo Nordisk or Eli Lilly.